Study Escalating Doses of PM01183 in Combination With Fixed Doxorubicin in Patients With Specific Advanced Unresectable Solid Tumors

Phase 1

Completed

• Conditions: Endometrial Adenocarcinomas; Small-cell Lung Cancer With Less Than 2 Prior Cytotoxic-containing Lines of Therapy; Neuroendocrine Tumors
• Interventions: Drug: lurbinectedin (PM01183); Drug: Doxorubicin

• Registration Number: NCT01970540
• Lead Sponsor: PharmaMar

Brief Summary

Phase I Multicenter, Open-label, Clinical and Pharmacokinetic Study of PM01183 in Combination with Fixed Doxorubicin in Non- Heavily Pretreated Patients with Selected Advanced Solid Tumors to determine the maximum tolerated dose (MTD) and the recommended dose (RD) of PM01183 in combination with doxorubicin, to characterize the safety profile and feasibility of this combination, to characterize the pharmacokinetics (PK) of this combination, to obtain preliminary information on the clinical antitumor activity,to explore the feasibility, safety and efficacy of a potential improvable dose of this combination in selected tumor types \[i.e. small cell lung cancer (SCLC) and endometrial cáncer\] and to evaluate the pharmacogenomics (PGx) in tumor samples of patients exposed to PM01183 and doxorubicin at the RD in order to assess potential markers of response and/or resistance.

Detailed Description

The study has currently met its primary end point and is now recruiting patients to be treated at the RD expansion cohort of selected tumor types, specifically: endometrial adenocarcinomas, neuroendocrine tumors, and small-cell lung cancer (SCLC).

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Study Start: 2011-05-25
• Study First Submitted: 2013-10-22
• Study First Submitted QC: 2013-10-22
• Study First Posted: 2013-10-28
• Primary Completion: 2017-08-09
• Study Completion: 2017-08-09
• Status Verified: 2020-01
• Results First Submitted: 2020-01-20
• Results First Submitted QC: 2020-02-24
• Last Update Submitted: 2020-02-24
• Results First Posted: 2020-03-09
• Last Update Posted: 2020-03-09

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 122

Inclusion Criteria

• Voluntarily written informed consent

• Age: between 18 and 75 years (both inclusive).

• Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤ 1. Cohort of patients with SCLC and endometrial cáncer ECOG PS ≤ 2.

• Life expectancy ≥ 3 months.

• Patients with a histologically/cytologically confirmed diagnosis of advanced disease of any of the following tumors:

  1. Breast cancer
  2. Soft-tissue sarcoma
  3. Primary bone sarcomas.
  4. Gynecologic tumors (endometrial adenocarcinomas, epithelial ovarian cancer...)
  5. Hepatocellular carcinoma
  6. Gastroenteropancreatic neuroendocrine tumors
  7. Small cell lung cancer (SCLC)
  8. Gastric cancer
  9. Bladder cancer
  10. Adenocarcinoma of unknown primary site

• At least three weeks since the last anticancer therapy, including radiotherapy

• Adequate bone marrow, renal, hepatic, and metabolic function

• Left ventricular ejection fraction (LVEF) by echocardiogram (ECHO) or multiple-gated acquisition (MUGA) scan within normal range (according to institutional standards).

• Women of childbearing potential must have a negative serum pregnancy test before study entry. Both women and men must agree to use a medically acceptable method of contraception throughout the treatment period and for six weeks after discontinuation of treatment

Read More

Exclusion Criteria

• Concomitant diseases/conditions:

  • History or presence of unstable angina, myocardial infarction, congestive heart failure, or clinically significant valvular heart disease within last year.
  • Symptomatic or any uncontrolled arrhythmia
  • Ongoing chronic alcohol consumption, or cirrhosis
  • Active uncontrolled infection.
  • Known human immunodeficiency virus (HIV) infection.
  • Any other major illness that, in the Investigator's judgment

• Brain metastases or leptomeningeal disease involvement.

• Men or women of childbearing potential who are not using an effective method of contraception

• Patients who have had radiation therapy in more than 35% of the bone marrow. This criterion will not apply to cohort of patients with SCLC and endometrial cáncer.

• History of previous bone marrow and/or stem cell transplantation.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
lurbinectedin (PM01183) / doxorubicin	lurbinectedin (PM01183)	-
lurbinectedin (PM01183) / doxorubicin	Doxorubicin	-

Primary Outcome Measures

Name	Time	Method
Maximum Tolerated Dose (MTD)	During the first cycle of treatment, up to 28 days	A minimum of three patients will be included at each DL. If no patients experience a DLT during Cycle 1, the dose will be escalated. If one of three patients experiences a DLT, three additional patients will be included at that level. If \>1 evaluable patient during dose escalation at a given DL experience a DLT during Cycle 1, that DL will be considered the MTD and dose escalation will be terminated, except if all DLTs are related to neutropenia exclusively, in which case dose escalation may be resumed as originally planned in a new cohort of patients but with compulsory primary G-CSF prophylaxis.
Recommended Dose (RD)	During the first cycle of treatment, up to 28 days	The DL immediately below the MTD, or DL4 if the MTD is not yet defined during dose escalation before the last DL (i.e., DL4) is reached, was to be initially expanded up to a minimum of nine evaluable patients. If less than three among the first nine evaluable patients treated within the expansion cohort experience a DLT during Cycle 1, this DL will be the RD.
Number of Participants With Dose-limiting Toxicities	During the first cycle of treatment, up to 28 days	DLT,dose-limiting toxicity Patients enrolled into this study were originally not allowed to receive primary G-CSF prophylaxis. However, the finding of dose-limiting febrile neutropenia in two patients treated at dose level I in the present study (see below) suggested that increasing doses of the DOX/PM01183 combination might require primary G-CSF prophylaxis to decrease the risk of febrile neutropenia. Therefore, a separate dose escalation was established to define the MTD and the RD of the DOX/PM01183 combination with compulsory primary G-CSF prophylaxis.

Secondary Outcome Measures

Name	Time	Method
Progression-free Survival	Time from the date of first administration to the date of PD or death (of any cause), whichever came first, assessed up to 72 months	Progression-free survival (PFS) is defined as the time from the date of first infusion of study treatment to the date of progression or death (due to any cause). If progression or death has not occurred at the time of the analysis, the PFS was censored on the date of last tumor evaluation.
Duration of Response	Time from the time measurement criteria are met for complete response, whichever is first recorded, until the first date in which progressive disease is objectively documented or the date of death, assessed up to 72 months	The duration of overall response was measured from the time measurement criteria are met for complete response (CR)/ PR, whichever is first recorded, until the first date in which progressive disease is objectively documented (taking as reference for progressive disease the smallest measurements recorded since the treatment started) or the date of death. In absence of disease progression or death, the duration of response was censored on the date of last tumor evaluation.
Overall Survival	Time from the date of first administration to the date of death (of any cause), assessed up to 72 months	Overall survival (OS) is defined as the time from the date of first infusion of study treatment to the date of death (due to any cause). Patients with no documented death were censored at the last date they are known to be alive
Best Overall Tumor Response	Tumor assessments were done every six weeks up to study completion	Tumor response was evaluated according to the RECIST v.1.1 for target lesions and assessed by computed tomography (CT) scans or magnetic resonance imagings (MRIs): Progressive disease (PD) is declared when there is an increase in sum of target disease ≥ 20%, stable diease (SD) when the change is \> -30% and ≤ 20%, partial response (PR) when there is a decrease in sum of target disease ≥ 30%, and complete response (CR) when all lesions have disappeared or all lesions have disapeared and all nodal disease is \< 10 mm each.

Trial Locations

Locations (7)

Hospital Ramón Y Cajal; 🇪🇸 Madrid, Spain

Fundación Instituto Valenciano de Oncología; 🇪🇸 Valencia, Spain

Hospital Universitari Vall D'Hebron; 🇪🇸 Barcelona, Spain

Hospital Universitario Madrid Sanchinarro; 🇪🇸 Madrid, Spain

Hospital Universitario Fundación Jiménez; 🇪🇸 Madrid, Spain

Centro Oncológico Md Anderson International España; 🇪🇸 Madrid, Spain

UCLH (University College London Hospitals); 🇬🇧 London, United Kingdom